603014 威高血净
已收盘 02-10 15:00:00
资讯
新帖
简况
每周股票复盘：威高血净（603014）募集资金现金管理未到期余额24,000万元
证券之星 · 02-08
每周股票复盘：威高血净（603014）募集资金现金管理未到期余额24,000万元
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回的公告，2月4日股价上涨0.17%
证券之星 · 02-04
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回的公告，2月4日股价上涨0.17%
每周股票复盘：威高血净（603014）筹划收购普瑞医药100%股权
证券之星 · 02-01
每周股票复盘：威高血净（603014）筹划收购普瑞医药100%股权
每周股票复盘：威高血净（603014）闲置募资赎回2.35亿获益32.62万
证券之星 · 01-18
每周股票复盘：威高血净（603014）闲置募资赎回2.35亿获益32.62万
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回情况，1月13日股价下跌0.46%
证券之星 · 01-13
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回情况，1月13日股价下跌0.46%
每周股票复盘：威高血净（603014）拟85.11亿收购威高普瑞
证券之星 · 01-11
每周股票复盘：威高血净（603014）拟85.11亿收购威高普瑞
威高血净拟85亿溢价资产置换 构建“血净+药包+生物制药上游”新生态
中国网财经 · 01-08
威高血净拟85亿溢价资产置换 构建“血净+药包+生物制药上游”新生态
【机构调研记录】嘉实基金调研威高血净、立高食品
证券之星 · 01-08
【机构调研记录】嘉实基金调研威高血净、立高食品
603014，重大资产重组
数据宝 · 01-05
603014，重大资产重组
威高血净最新公告：拟收购威高普瑞100%股权交易价格为85.11亿元
证券之星 · 01-05
威高血净最新公告：拟收购威高普瑞100%股权交易价格为85.11亿元
每周股票复盘：威高血净（603014）筹划收购普瑞医药100%股权
证券之星 · 01-02
每周股票复盘：威高血净（603014）筹划收购普瑞医药100%股权
威高血净（603014）披露发行股份购买资产暨关联交易事项进展公告，12月29日股价下跌1.57%
证券之星 · 2025-12-29
威高血净（603014）披露发行股份购买资产暨关联交易事项进展公告，12月29日股价下跌1.57%
威高血净：海外业务目前重点布局东南亚、南美、东欧、北非等市场
证券日报 · 2025-12-23
威高血净：海外业务目前重点布局东南亚、南美、东欧、北非等市场
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回情况，12月2日股价下跌0.95%
证券之星 · 2025-12-02
威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回情况，12月2日股价下跌0.95%
威高血净（603014）披露发行股份购买资产暨关联交易事项进展公告，11月28日股价上涨1.13%
证券之星 · 2025-11-28
威高血净（603014）披露发行股份购买资产暨关联交易事项进展公告，11月28日股价上涨1.13%
每周股票复盘：威高血净（603014）拟对合营企业增资0.725亿元
证券之星 · 2025-11-23
每周股票复盘：威高血净（603014）拟对合营企业增资0.725亿元
威高血净（603014）披露对合营企业同比例增资暨关联交易公告，11月20日股价下跌0.81%
证券之星 · 2025-11-20
威高血净（603014）披露对合营企业同比例增资暨关联交易公告，11月20日股价下跌0.81%
威高血净(603014.SH)与泰尔茂中国拟对威高泰尔茂进行同比例增资
智通财经 · 2025-11-20
威高血净(603014.SH)与泰尔茂中国拟对威高泰尔茂进行同比例增资
威高血净（603014）125.47万股限售股将于11月19日解禁，占总股本0.3%
证券之星 · 2025-11-19
威高血净（603014）125.47万股限售股将于11月19日解禁，占总股本0.3%
每周股票复盘：威高血净（603014）125万股限售股将上市流通
证券之星 · 2025-11-16
每周股票复盘：威高血净（603014）125万股限售股将上市流通
加载更多
公司概况
公司名称：
山东威高血液净化制品股份有限公司
所属行业：
专用设备制造业
上市日期：
2025-05-19
主营业务：
山东威高血液净化制品股份有限公司的主营业务是血液净化医用制品的研发、生产和销售。公司的主要产品是血液透析器、血液透析管路、血液透析机以及腹膜透析液。
发行价格：
26.50
{"stockData":{"symbol":"603014","market":"SH","secType":"STK","nameCN":"威高血净","latestPrice":40.51,"timestamp":1770706800000,"preClose":40.26,"halted":0,"volume":881003,"delay":0,"changeRate":0.0062,"floatShares":39367300,"shares":418000000,"eps":1.1356,"marketStatus":"已收盘","change":0.25,"latestTime":"02-10 15:00:00","open":40.24,"high":40.69,"low":40.15,"amount":35605100,"amplitude":0.0134,"askPrice":40.51,"askSize":2,"bidPrice":40.5,"bidSize":57,"shortable":0,"etf":0,"ttmEps":1.1356,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"adjPreClose":40.26,"symbolType":"stock","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":44.29,"lowLimit":36.23,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":417754066,"isCdr":false,"pbRate":2.42,"roa":"--","peRate":35.672772,"roe":"5.44%","epsLYR":1.21,"committee":0.878505,"marketValue":16923000000,"turnoverRate":0.0224,"status":0,"floatMarketCap":1595000000},"requestUrl":"/m/hq/s/603014","defaultTab":"news","newsList":[{"id":"2609552660","title":"每周股票复盘：威高血净（603014）募集资金现金管理未到期余额24,000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609552660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609552660?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:58","pubTimestamp":1770490689,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，威高血净报收于40.07元，较上周的40.66元下跌1.45%。本周，威高血净2月2日盘中最高价报40.87元。威高血净当前最新总市值167.39亿元，在医疗器械板块市值排名17/129，在两市A股市值排名1255/5186。公司公告汇总山东威高血液净化制品股份有限公司使用暂时闲置募集资金购买的结构性存款到期赎回，赎回金额合计23,500万元，获得实际收益36.43万元。截至公告日，公司使用闲置募集资金进行现金管理未到期余额为24,000万元，未超出董事会授权额度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2608980273","title":"威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回的公告，2月4日股价上涨0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608980273","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608980273?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:48","pubTimestamp":1770216495,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，威高血净报收于40.25元，较前一交易日上涨0.17%，最新总市值为168.15亿元。该股当日开盘40.15元，最高40.3元，最低39.9元，成交额达3662.68万元，换手率为2.32%。公告显示，公司使用暂时闲置募集资金购买的结构性存款到期赎回，赎回金额合计23,500万元，获得实际收益36.43万元。截至公告日，公司使用闲置募集资金进行现金管理未到期余额为24,000万元，未超出董事会授权额度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2608070665","title":"每周股票复盘：威高血净（603014）筹划收购普瑞医药100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070665","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070665?lang=zh_cn&edition=full","pubTime":"2026-02-01 04:08","pubTimestamp":1769890092,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，威高血净报收于40.66元，较上周的41.62元下跌2.31%。本周，威高血净1月26日盘中最高价报42.3元。威高血净当前最新总市值169.86亿元，在医疗器械板块市值排名16/127，在两市A股市值排名1255/5184。本周关注点公司公告汇总：威高血净拟发行股份购买威高普瑞医药100%股权，构成重大资产重组。公司股票已于2025年11月3日起复牌。本次交易进展已按规定履行信息披露义务，后续将根据进展情况持续披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014","000978.SH"],"gpt_icon":0},{"id":"2604192304","title":"每周股票复盘：威高血净（603014）闲置募资赎回2.35亿获益32.62万","url":"https://stock-news.laohu8.com/highlight/detail?id=2604192304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604192304?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:24","pubTimestamp":1768677848,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，威高血净报收于41.2元，较上周的41.38元下跌0.43%。本周，威高血净1月13日盘中最高价报42.15元。威高血净当前最新总市值172.11亿元，在医疗器械板块市值排名16/127，在两市A股市值排名1225/5183。公司公告汇总山东威高血液净化制品股份有限公司关于使用暂时闲置募集资金进行现金管理到期赎回的公告：公司近期赎回民生银行威海分行和威海银行股份有限公司东城支行的结构性存款产品，合计金额23,500万元，获得实际收益32.62万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2603383846","title":"威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回情况，1月13日股价下跌0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603383846","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603383846?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:30","pubTimestamp":1768314628,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，威高血净报收于41.39元，较前一交易日下跌0.46%，最新总市值为172.91亿元。公司于2025年5月27日经董事会及监事会审议通过相关现金管理议案，授权使用最高不超过74,000万元的闲置募集资金进行现金管理。截至公告日，未到期现金管理余额为36,000万元，未超出授权额度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2602953593","title":"每周股票复盘：威高血净（603014）拟85.11亿收购威高普瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2602953593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602953593?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:45","pubTimestamp":1768070710,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，威高血净报收于41.38元，较上周的39.63元上涨4.42%。本周，威高血净1月6日盘中最高价报43.63元。本周关注点交易信息汇总：威高血净拟以85.11亿元对价发行股份收购威高普瑞100%股权。威高股份及其一致行动人合计持有上市公司股份比例由74.18%增至84.36%，本次收购符合免于发出要约条件。公司公告汇总公司于2026年1月5日召开第二届董事会第二十次会议，审议通过发行股份购买威高普瑞100%股权的交易方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2601333480","title":"威高血净拟85亿溢价资产置换 构建“血净+药包+生物制药上游”新生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2601333480","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601333480?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:28","pubTimestamp":1767835680,"startTime":"0","endTime":"0","summary":"中国网财经1月8日讯 近日，威高血净(603014.SH)发布公告称，公司拟通过发行股份的方式，从威高股份(01066.HK)、威海盛熙企业管理咨询中心(有限合伙)和威海瑞明企业管理咨询合伙企业(有限合 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260108/c673846512.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260108/c673846512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["603014","BK0251"],"gpt_icon":0},{"id":"2601870653","title":"【机构调研记录】嘉实基金调研威高血净、立高食品","url":"https://stock-news.laohu8.com/highlight/detail?id=2601870653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601870653?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:11","pubTimestamp":1767831078,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月7日披露的机构调研信息，嘉实基金近期对2家上市公司进行了调研，相关名单如下：1）威高血净 调研纪要：公司致力于成为生物制药上游整体解决方案提供商，以高端滤器为核心打造一体化耗材平台。嘉实基金成立于1999年，截至目前，资产管理规模11620.41亿元，排名7/212；资产管理规模7323.04亿元，排名7/212；管理公募基金数635只，排名10/212；旗下公募基金经理100人，排名6/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800005460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0226","300973","BK0251"],"gpt_icon":0},{"id":"2601882162","title":"603014，重大资产重组","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882162","media":"数据宝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601882162?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:41","pubTimestamp":1767620460,"startTime":"0","endTime":"0","summary":"股价上涨的有10只，涨幅居前的有旗滨集团、石基信息、天赐材料等，今日涨幅分别为5.06%、4.52%、3.69%。3股净买入金额均超1亿元，蓝色光标获机构净买入1.86亿元，居首；其次是海科新源、东微半导，机构净买入金额分别为1.17亿元、1.1亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-05/doc-inhfhpmf1927301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2601589883","title":"威高血净最新公告：拟收购威高普瑞100%股权交易价格为85.11亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601589883","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601589883?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:10","pubTimestamp":1767611404,"startTime":"0","endTime":"0","summary":"威高血净(603014.SH)公告称，威高股份及其一致行动人拟通过发行股份的方式，购买威高普瑞100%的股权。本次收购完成后，威高股份及其一致行动人将合计持有威高血净84.36%的股份，不会影响上市公司的上市地位。标的公司股权全部权益的评估值为85.11亿元。本次交易后，上市公司主营业务将新增预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500032524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2600003675","title":"每周股票复盘：威高血净（603014）筹划收购普瑞医药100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2600003675","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600003675?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:34","pubTimestamp":1767296050,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，威高血净报收于40.78元，较上周的40.95元下跌0.42%。本周，威高血净12月26日盘中最高价报41.36元。威高血净当前最新总市值165.56亿元，在医疗器械板块市值排名15/127，在两市A股市值排名1187/5181。公司公告汇总山东威高血液净化制品股份有限公司正在筹划以发行股份方式购买山东威高普瑞医药包装有限公司100%股权，预计构成重大资产重组及关联交易，不构成重组上市。公司股票已于2025年10月20日起停牌，后于11月3日复牌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014","000978.SH"],"gpt_icon":0},{"id":"2595786716","title":"威高血净（603014）披露发行股份购买资产暨关联交易事项进展公告，12月29日股价下跌1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595786716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595786716?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:45","pubTimestamp":1767001536,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，威高血净报收于40.14元，较前一交易日下跌1.57%，最新总市值为167.69亿元。该股当日开盘40.74元，最高40.77元，最低40.11元，成交额达5975.75万元，换手率为3.76%。同日，公司发布关于发行股份购买资产暨关联交易事项的进展公告。公告显示，山东威高血液净化制品股份有限公司正在筹划以发行股份方式购买山东威高普瑞医药包装有限公司100%股权，预计构成重大资产重组及关联交易，不构成重组上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900024440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"gpt_icon":0},{"id":"2593418862","title":"威高血净：海外业务目前重点布局东南亚、南美、东欧、北非等市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418862","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418862?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:02","pubTimestamp":1766494972,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，威高血净在互动平台回答投资者提问时表示，海外业务目前重点布局东南亚、南美、东欧、北非等市场，欧美日等市场为长期战略市场。海外销售团队及本地化方面，已在厄瓜多尔、印度尼西亚设立子公司，未来预计在多个国家进行本地化布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599740564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2588059415","title":"威高血净（603014）披露使用暂时闲置募集资金进行现金管理到期赎回情况，12月2日股价下跌0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588059415?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:21","pubTimestamp":1764685267,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，威高血净报收于40.85元，较前一交易日下跌0.95%，最新总市值为170.65亿元。该股当日开盘41.24元，最高41.65元，最低40.8元，成交额达7319.78万元，换手率为4.52%。公司近日发布公告称，山东威高血液净化制品股份有限公司使用暂时闲置募集资金进行现金管理，近期赎回多笔结构性存款产品，合计赎回金额76,000万元，获得实际收益共计99.40万元。截至公告日，未到期现金管理余额为5,500万元，未超出董事会授权额度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2586193738","title":"威高血净（603014）披露发行股份购买资产暨关联交易事项进展公告，11月28日股价上涨1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586193738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586193738?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:15","pubTimestamp":1764339340,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，威高血净报收于40.43元，较前一交易日上涨1.13%，最新总市值为168.9亿元。公司近日发布公告称，山东威高血液净化制品股份有限公司正在筹划以发行股份方式购买山东威高普瑞医药包装有限公司100%股权，本次交易构成重大资产重组及关联交易，不构成重组上市。公司股票曾于2025年10月20日起停牌，后于11月3日复牌。本次交易尚需董事会再次审议、股东会批准及监管机构核准，能否实施存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2585103677","title":"每周股票复盘：威高血净（603014）拟对合营企业增资0.725亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103677","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103677?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:30","pubTimestamp":1763836236,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，威高血净报收于39.84元，较上周的41.58元下跌4.18%。山东威高血液净化制品股份有限公司拟与泰尔茂（中国）投资有限公司对合营企业威高泰尔茂（威海）医疗制品有限公司同比例增资，公司拟增资0.725亿元人民币。本次增资后，威高泰尔茂注册资本将由1.6亿元增至3.05亿元，公司持股比例保持50%不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2584413700","title":"威高血净（603014）披露对合营企业同比例增资暨关联交易公告，11月20日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584413700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584413700?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:19","pubTimestamp":1763648359,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，威高血净报收于40.26元，较前一交易日下跌0.81%，最新总市值为168.19亿元。该股当日开盘40.6元，最高40.98元，最低40.09元，成交额达8127.26万元，换手率为5.1%。近日，山东威高血液净化制品股份有限公司发布公告称，公司拟与泰尔茂（中国）投资有限公司对合营企业威高泰尔茂（威海）医疗制品有限公司同比例增资，公司拟增资0.725亿元人民币。本次增资后，威高泰尔茂注册资本将由1.6亿元增至3.05亿元，公司持股比例保持50%不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","603014"],"gpt_icon":0},{"id":"2584513184","title":"威高血净(603014.SH)与泰尔茂中国拟对威高泰尔茂进行同比例增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2584513184","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584513184?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:11","pubTimestamp":1763629898,"startTime":"0","endTime":"0","summary":"智通财经APP讯，威高血净(603014.SH)发布公告，结合公司战略规划，为满足腹膜透析液业务的发展需要，公司与泰尔茂中国拟对威高泰尔茂进行同比例增资，其中公司拟增资金额为0.725亿元人民币。本次增资完成后，威高泰尔茂的注册资本将由1.6亿元人民币增加至3.05亿元人民币，公司对威高泰尔茂的持股比例不变，仍为50%，威高泰尔茂仍属于公司与泰尔茂中国共同控制的合营企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603014","BK0251"],"gpt_icon":0},{"id":"2584962206","title":"威高血净（603014）125.47万股限售股将于11月19日解禁，占总股本0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584962206","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584962206?lang=zh_cn&edition=full","pubTime":"2025-11-19 08:05","pubTimestamp":1763510709,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，威高血净于11月19日将有125.47万股限售股份解禁，为公司首发机构配售股份，占公司总股本0.3%。本次解禁后，公司还有3.78亿股限售股份，占总股本90.58%。威高血净主营业务：专注于血液净化医用制品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900004946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"gpt_icon":0},{"id":"2583010656","title":"每周股票复盘：威高血净（603014）125万股限售股将上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2583010656","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583010656?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:47","pubTimestamp":1763228829,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，威高血净报收于41.58元，较上周的45.27元下跌8.15%。公司公告汇总山东威高血液净化制品股份有限公司首次公开发行网下配售限售股共计1,254,745股，占公司总股本0.3%，锁定期为6个月，将于2025年11月19日起上市流通。本次解除限售股份数量为1,254,745股，上市流通后有限售条件流通股相应减少，无限售条件流通股增加。保荐机构华泰联合证券对本次限售股上市流通无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603014","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770771144924,"stockEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":-0.021},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.0285},{"period":"1year","weight":0.5287},{"period":"ytd","weight":0.0222}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0019},{"period":"3month","weight":0.0321},{"period":"6month","weight":0.126},{"period":"1year","weight":0.2427},{"period":"ytd","weight":0.0402}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东威高血液净化制品股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"24821人(较上一季度减少20.95%)","perCapita":"1586股","listingDate":"2025-05-19","address":"山东省威海市环翠区威海火炬高技术产业开发区威高西路7号","registeredCapital":"41775万元","survey":" 山东威高血液净化制品股份有限公司的主营业务是血液净化医用制品的研发、生产和销售。公司的主要产品是血液透析器、血液透析管路、血液透析机以及腹膜透析液。","listedPrice":26.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"威高血净(603014)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供威高血净(603014)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"威高血净,603014,威高血净股票,威高血净股票老虎,威高血净股票老虎国际,威高血净行情,威高血净股票行情,威高血净股价,威高血净股市,威高血净股票价格,威高血净股票交易,威高血净股票购买,威高血净股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"威高血净(603014)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供威高血净(603014)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}